Protalix BioTherapeutics, Inc. (PLX)
After hours:
| Previous close | 1.1800 |
| Open | 1.1900 |
| Bid | 1.1300 x 800 |
| Ask | 1.1400 x 1800 |
| Day's range | 1.0900 - 1.2200 |
| 52-week range | 1.0900 - 3.5500 |
| Volume | |
| Avg. volume | 360,144 |
| Market cap | 84.01M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 12.78 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2023, and provided a business update.
- PR Newswire
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.
- PR Newswire
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.
